TrialJCO precision oncology2024

Randomized Phase II Study of Gemcitabine With or Without ATR Inhibitor Berzosertib in Platinum-Resistant Ovarian Cancer: Final Overall Survival and Biomarker Analyses.

Panagiotis A Konstantinopoulos et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.